Cargando…
DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18
Sorafenib (SFN) is a multi-kinase inhibitor drug for the treatment of advanced hepatocellular carcinoma (HCC), but its limited efficacy is a major obstacle to the clinical outcomes of patients with HCC. We aimed to explore a novel molecular mechanism underlying the chemosensitivity of HCC to SFN, an...
Autores principales: | Gan, Hairun, Li, Luting, Hu, Xinyan, Cai, Jianxun, Hu, Xiaojun, Zhang, Haopei, Zhao, Ni, Xu, Xiwei, Guo, Hui, Pang, Pengfei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629112/ https://www.ncbi.nlm.nih.gov/pubmed/36310384 http://dx.doi.org/10.1080/15384047.2022.2135960 |
Ejemplares similares
-
DDX24 promotes metastasis by regulating RPL5 in non‐small cell lung cancer
por: Hu, Xinyan, et al.
Publicado: (2022) -
DDX24 Mutation Alters NPM1 Phase Behavior and Disrupts Nucleolar Homeostasis in Vascular Malformations
por: Zhang, Haopei, et al.
Publicado: (2023) -
Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma
por: Hu, Xinyan, et al.
Publicado: (2023) -
Identification of potential genetic Loci and polygenic risk model for Budd-Chiari syndrome in Chinese population
por: Hu, Xiaojun, et al.
Publicado: (2023) -
Five novel RB1 gene mutations and genotype–phenotype correlations in Chinese children with retinoblastoma
por: Li, Luting, et al.
Publicado: (2022)